CEL-SCI Announces $15 Million Commitment For Cancer Drug Manufacturing Facility (PR Newswire via Yahoo! Finance)
CEL-SCI Corporation has signed a letter of intent with BioProperties, Inc., a privately held real estate firm specialized in the biomedical sector, to acquire and build out to CEL-SCI's specifications a turn-key CGMP drug manufacturing facility for CEL-SCI's cancer product Multikine .

Cattle Update: Expanded Dose Range For Rumensin Now Approved (CattleNetwork.com)
GREENFIELD , Ind. : January 22, 2007 The U.S. Food and Drug Administration (FDA) has granted an expanded dose range approval for Rumensin for improvement in feed efficiency and coccidiosis prevention and control in feedlot cattle.   The approval increases the upper end of the dose range to 40 grams per ton, on a 90 percent dry matter basis.